Eli Lilly (LLY) is in advanced talks to acquire Ventyx Biosciences (VTYX) for more than USD 1bln, according to WSJ citing sources

Eli Lilly (LLY) is in advanced talks to acquire Ventyx Biosciences (VTYX) for more than USD 1bln, according to WSJ citing sources.

Eli Lilly's potential acquisition of Ventyx Biosciences for over $1 billion marks a significant move in the pharmaceuticals sector, suggesting their strategy may be focused on expanding their biotechnology portfolio. This deal could create ripple effects across the industry, potentially driving M&A activity as peers react to Lilly's consolidation efforts and the strategic rationale behind the purchase.